A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Trial Profile

A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Masitinib (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 21 Sep 2017 This trial has been suspended in Slovakia.
    • 31 Aug 2017 Interim results presented in an AB Science media release.
    • 31 Aug 2017 According to an AB Science media release, the next interim analysis in this trial is expected with 50% of patients having reached the 96 week treatment duration. This interim analysis is anticipated in the first half of 2018 and the final results are expected in the second quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top